For this purpose, we generated a cohort of KrasG12D/MYOCD-/- (K-sgMYOCD, see Figure 1K-M for details) transgenic mice and randomized them for treatments with above combinational scheme after lung cancers were documented by CT scanning. The gene discussed is MYOCD; the disease is lung cancer.